

#### **Aspira Pathlab & Diagnostics Limited**

**Regd. Office:** Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086 CIN:L85100MH1973PLC289209

September 30, 2022

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

Sub: Disclosure under Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended ("SEBI Insider Trading Regulations")- Continual Disclosure

Dear Sir/Madam,

Please find enclosed herewith the following disclosures-

1. Form - C pursuant to Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Mr. Paresh Bhanji Bhanushali.

2. Form - C pursuant to Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Mrs. Geeta Paresh Bhanushali.

3. Form - C pursuant to Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Mr. Nikunj Velji Mange.

4. Form - C pursuant to Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Mrs. Shraddha Bhanushali.

5. Form - C pursuant to Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Mr. Raj Arvind Bhanushali.

6. Form - C pursuant to Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Mr. Jay Arvind Bhanushali.

We request you to treat this intimation as compliance with Regulation 7(2)(b) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and take the same on record.

Thanking You,

Yours Sincerely,

For Aspira Pathlab & Diagnostics Limited

Priya Pandey Company Secretary & Compliance Officer Encl: as above



#### PARESH BHANJI BHANUSHALI ADDRESS: A-9/100 SHASHTRI NAGAR, NEAR ONGC COLONY, VIDYAYIHAR EAST, MUMBAI, MAHARASHTRA - 400077

September 29, 2022

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

#### **Ref: ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

# Sub: Regulation 7 (2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015

Dear Sir,

Please find enclosed herewith the Regulation 7(2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015 as informed by me in Form C regarding disposal of Equity Shares of the Company through market.

Please take it on your record.

Thanking You,

(Paresh Bhanji Bhanushali)

Encl: - as above

CC:-ASPIRA PATHLAB & DIAGNOSTICS LIMITED Flat NO.2, R.D. Shah Bldg, Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai - 400086

#### <u>FORM C</u>

#### SEBI (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7(2) read with Regulation 6(2) – Continual Disclosure]

Name of the company: Aspira Pathlab & Diagnostics Limited

**ISIN of the company:** INE500C01017

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed companyand immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Name, PAN, CIN/DIN, & address with contact nos.	of Person (Promoter/ member of the	Securitie prior to <del>acquisiti</del> disposal Type of securiti	es held <del>on</del> / No. and	Securities <del>acqui</del> Type of No. securities (For eg.			Transac	<del>acquisition</del> disposal Type of securities	n/ No. and	Date of <del>all</del> <del>advice/ acc of shares</del> /c shares,spec From	<del>quisition</del> disposal of	intimation	acquisition /disposal (on market/ public/ rights/	Exchange on which the trade was executed
	gnated person/ Director s/immedia terelative to/others etc.)	eg. – Shares Warrant	holding	• •			se/sale Pledge / Revocat ion /	- Shares, Warrants, Converti ble Debentur es, Rights entitleme nt, etc.)	olding			of of In tra ES	preferential offer/ off market/ Inter-se transfer, ESOPs, etc.)	
Paresh Bhanji Bhanushali PAN: ACGPB1990G Address: A-9/100 Shashtri Nagar, Near ONGC Colony, Vidyayihar East, Mumbai, Maharashtra - 400077		Shares	153000 & 1.49%	Equity Shares	10,000	4,30,250	Sale	Equity Shares	1,43,000 (1.39%)	26-09-2022	26-09-2022	29-09-2022	Market Sale	BSE
Contact No.: 9967678866														

**Note:** (i) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015. (ii) Value of transaction excludes taxes/brokerage/any other charges

(Paresh Bhanji Bhanushali) Date: 29-09-2022 Place: Mumbai

#### GEETA PARESH BHANUSHALI ADDRESS: A-9/100 SHASHTRI NAGAR, NEAR ONGC COLONY, VIDYAYIHAR EAST, MUMBAI, MAHARASHTRA - 400077

**September 29, 2022** 

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

#### **Ref: ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

# Sub: Regulation 7 (2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015

Dear Sir,

Please find enclosed herewith the Regulation 7(2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015 as informed by me in Form C regarding disposal of Equity Shares of the Company through market.

Please take it on your record.

Thanking You,

(Geeta Paresh Bhanushali)

Encl: - as above

CC:-ASPIRA PATHLAB & DIAGNOSTICS LIMITED Flat NO.2, R.D. Shah Bldg, Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai - 400086

SEBI (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7 (2) read with Regulation 6(2) – Continual Disclosure]

Name of the company: Aspira Pathlab & Diagnostics Limited

**ISIN of the company:** INE500C01017

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Name, PAN, CIN/DIN, & address with contact nos.	Category of Person (Promoter /member of the promoter group/de signated person/ Director s/immedi ate relative to/others etc.)	<del>acquisitic</del> disposal Type of securiti es (For	No. and % of share holding	Securities a Type of securities (For eg. - Shares, Warrants, Convertib le Debenture s, Rights entitleme nt, etc.)	No.	l/Dispose	Transac tion Type (Purcha se/sale Pledge / Revocat ion /	acquisitior disposal Type of securities (For eg. – Shares,	No. and	Date of <del>alk</del> <del>advice/ acq shares</del> /disp shares,spec From	uisition of osal of	intimation	Mode of acquisition /disposal (on market/ public/ rights/ preferential offer/ off market/ Inter-se transfer, ESOPs, etc.)	
Geeta Paresh Bhanushali <b>PAN:</b> AEXPM7870F <b>Address:</b> A-9/100 Shashtri Nagar, Near ONGC Colony, Vidyayihar East, Mumbai, Maharashtra - 400077 <b>Contact No.</b> : 9967678866	Member of Promoter Group/ Immediate relative of Promoter	Shares	98,300 & 0.96%	Equity Shares	10000	4,30,000	Sale	Equity Shares	88,300 (0.86%)		26-09-2022	29-09-2022	Market Sale	BSE

**Note:** (i) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015. (ii) Value of transaction excludes taxes/brokerage/any other charges

eeta

(Geeta Paresh Bhanushali) Date: 29-09-2022 Place: Mumbai

#### NIKUNJ VELJI MANGE ADDRESS: C-34, KONARK INDRAPRASHTH, SARVODAYA NAGAR, VILLAGE NAHUR, MULUND (W), MUMBAI – 400080

September 29, 2022

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

### Ref: ASPIRA PATHLAB & DIAGNOSTICS LIMITED

# Sub: Regulation 7 (2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015

Dear Sir,

Please find enclosed herewith the Regulation 7(2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015 as informed by me in Form C regarding acquisition of Equity Shares of the Company through market.

Please take it on your record.

Thanking You,

(Nikunj Velji Mange)

Encl: - as above

CC:-

ASPIRA PATHLAB & DIAGNOSTICS LIMITED Flat NO.2, R.D. Shah Bldg, Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai - 400086

### SEBI (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7 (2) read with Regulation 6(2) - Continual Disclosure]

Name of the company: Aspira Pathlab & Diagnostics Limited

ISIN of the company: INE500C01017

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed companyand immediate relatives of Name, PAN\_CTN/(NN)\_\_\_\_Category\_\_\_\_\_\_

Name, PAN, CIN/DIN, & address with contact nos. (Promote /member of the promoter group/de signated person/ Director s/immedi ate relative to/others etc.)	prior to acquisit disposal Type of securiti es (For eg. – Shares Warrant s, Convert	ion/ No. and % of share holding	Securit Type of securit ies (For eg. - Shares , Warran ts, Conver tib le Debent ures, Rights entitle ment,	f No.	Value	Transac tion Type (Purcha se/sale Pledge / Revocat ion / Invocati	Type of securities For eg.	n/ No. and % of shareh olding	t Date of a <del>advice/</del> a shares <del>/d</del> <del>shares</del> ,sp From	cquisition of i <del>sposal of</del>	Date of intimation to company	acquisition	
Nikunj Velji Mange Director PAN: AWUPM4484A Address: C-34, Konark Indraprashth, Sarvodaya Nagar, Village Nahur, Mulund (W), Mumbai – 400080 Contact No.:9372100646	Equity Shares	73,611	<b>etc.)</b> Equity Shares	7,750	3,35,700	Purchase	Equity Shares	81,361 (0.79%)	26-09-2022	27-09-2022	29-09-2022	Market Purchase	BSE
Note: (i) "Securit	ioc" chall l												

**Note:** (i) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015. (ii) Value of transaction excludes taxes/brokerage/any other charges

(Nikunj Velji Mange) Date: 29-09-2022 Place: Mumbai

#### SHRADDHA BHANUSHALI ADDRESS: C-34, KONARK INDRAPRASHTH, SARVODAYA NAGAR, VILLAGE NAHUR, MULUND (W), MUMBAI – 400080

@n : #4

Qn . . . .

September 29, 2022

@n ! #h

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

Qu . . . .

#### **Ref: ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

## Sub: Regulation 7 (2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015

Dear Sir,

Please find enclosed herewith the Regulation 7(2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015 as informed by me in Form C regarding acquisition of Equity Shares of the Company through market.

Please take it on your record.

Thanking You,

(&) Manushali'

(Shraddha Bhanushali)

Encl: - as above

CC:-ASPIRA PATHLAB & DIAGNOSTICS LIMITED Flat NO.2, R.D. Shah Bldg, Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai

400086

#### SEBI (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7 (2) read with Regulation 6(2) – Continual Disclosure]

Name of the company: Aspira Pathlab & Diagnostics Limited

**ISIN of the company:** INE500C01017

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed companyand immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Name, PAN, CIN/DIN, & address with contact nos.	Category	Securitie prior to acquisitie <del>disposal</del> Type of securiti es (For	es held on/ No. and % of share holding	Securiti Type of securit ies (For eg. - Shares , Warran ts, Conver tib le Debent ures, Rights	es acqu	Value	Transac tion Type (Purcha se/sale Pledge / Revocat ion /	acquisitior <del>disposal</del> Type of securities	No. and % of shareh	Date of <del>alle advice/</del> acq shares <del>/disp shares</del> ,spec From	uisition of <del>osal of</del>	Date of intimation to company		Exchange on which the trade was executed
Shraddha Bhanushali PAN: BPHPB0223F Address: C-34, Konark Indraprashth, Sarvodaya Nagar, Village Nahur, Mulund (W), Mumbai – 400080 Contact No.:9372100646	Immediate Relative of Director		56,178 & 0.55	and the second sec	6903	303481.73	Purchase	Shares	63,081 (0.61%)	27.09.2022	28.09.2022	29.09.2022	Market Purchase	BSE

*Note: (i)* "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015. *(ii)* Value of transaction excludes taxes/brokerage/any other charges

(Shraddha Bhanushali)

(Shraddha Bhanushali) Date: 29-09-2022 Place: Mumbai

#### RAJ ARVIND BHANUSHALI ADDRESS: C-34, KONARK INDRAPRASHTH, SARVODAYA NAGAR, VILLAGE NAHUR, MULUND (W), MUMBAI – 400080

September 29, 2022

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

#### **Ref: ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

# Sub: Regulation 7 (2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015

Dear Sir,

Please find enclosed herewith the Regulation 7(2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015 as informed by me in Form C regarding acquisition of Equity Shares of the Company through market.

Please take it on your record.

Thanking You,

(Raj Arvind Bhanushali)

Encl: - as above

CC:-ASPIRA PATHLAB & DIAGNOSTICS LIMITED Flat NO.2, R.D. Shah Bldg, Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai - 400086

#### SEBI (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7 (2) read with Regulation 6(2) – Continual Disclosure]

Name of the company: Aspira Pathlab & Diagnostics Limited

ISIN of the company: INE500C01017

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed companyand immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Name, PAN, CIN/DIN, & address with contact nos.	ofPerson (Promoter /member	prior to acquisition/			-	ired <del>/Dispo</del>	<del>sed</del>	acquisition/		t Date of <del>allotment</del> <del>advice/</del> acquisition of shares <del>/disposal of</del> <del>shares</del> ,specify		Date of intimation to company	Mode of acquisition / <del>/disposal</del> (on market/	Exchange on which the trade was
	group/de signated person/ Director s/immedi ate relative	es (For eg. – Shares Warrant s, Convert ible	% of share holding	securit ies	No.	Value	(Purcha se/sale Pledge / Revocat ion / Invocati on/ Others-	Type of securities (For eg. – Shares, Warrants, Converti ble Debentur es, Rights entitleme nt, etc.)	shareh	From	Το		public/ rights/ preferential offer/ off market/ Inter-se transfer, ESOPs, etc.)	executed
Raj Arvind Bhanushali PAN: CMKPB2466H Address: C-34, Konark Indraprashth, Sarvodaya Nagar, Village Nahur, Mulund (W), Mumbai – 400080 Contact No.: +1(919)593-9771 Total	Promoter Group	Equity Shares	43164 & 0.42%	Equity Shares	14800	6,42,250	Purchase		57,964 & 0.56%	26.09.2022	28.09.2022	29.09.2022	Market Purchase	BSE

**Note:** (i) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015. (ii) Value of transaction excludes taxes/brokerage/any other charges

(Raj Arvind Bhanushali) Date: 29-09-2022 Place: Mumbai

#### JAY ARVIND BHANUSHALI ADDRESS: C-34, KONARK INDRAPRASHTH, SARVODAYA NAGAR, VILLAGE NAHUR, MULUND (W), MUMBAI – 400080

An . The

September 29, 2022

-

- · · ·

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

#### **Ref: ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

# Sub: Regulation 7 (2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015

Dear Sir,

Please find enclosed herewith the Regulation 7(2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015 as informed by me in Form C regarding acquisition of Equity Shares of the Company through market.

Please take it on your record.

Thanking You,

(Jay Arvind Bhanushali)

Encl: - as above

CC:-ASPIRA PATHLAB & DIAGNOSTICS LIMITED Flat NO.2, R.D. Shah Bldg, Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai

400086

#### SEBI (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7 (2) read with Regulation 6(2) – Continual Disclosure]

ê

Name of the company: Aspira Pathlab & Diagnostics Limited

ISIN of the company: INE500C01017

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed companyand immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Name, PAN, CIN/DIN,	Category	Securitie	and the second se			ired <del>/Dispose</del>	e	Securities	heldpost	Date of a	lotment	Date of	Mode of	Exchange
, , , ,	ofPerson							acquisition		advice/ acquisition of		intimation	acquisition	on which
with contact nos.	(Promoter	acquisiti	on/					disposal		shares <del>/dis</del>	posal of	to company	<del>/disposal</del>	the trade
										<del>shares</del> ,specify			(on	was
of the promoter group/de signated person/ Director s/immedi ate relative to/others etc.)	es (For eg. – Shares Warrant	% of share holding	securit ies		Value	Pledge / Revocat ion /	securities (For eg.	shareh olding	From	Το		market/ public/ rights/ preferential offer/ off market/ Inter-se transfer, ESOPs, etc.)		
	Promoter Group	-	NIL	Equity Shares	11575	498255	Purchase	Equity Shares	11575 (0.11%)	23-09-2022	28-09-2022	29-09-2022	Market Purchase	BSE

**Note:** (*i*) "Securities" shall have the meaning as defined under regulation 2(1)(*i*) of SEBI (Prohibition of Insider Trading) Regulations, 2015. (*ii*) Value of transaction excludes taxes/brokerage/any other charges

(Jay Arvind Bhanushali) Date: 29-09-2022 Place: Mumbai